rethinkPeptides Search
Menu
Study breakdown

Animal Venom Peptides Can Both Damage and Protect DNA — Implications for Drug Development

evidence
The takeaway

Venom-derived peptides like melittin, mastoparan, and melectin can damage DNA directly or cause DNA lesions through oxidative stress, while some venom components show genoprotective effects — both properties relevant to potential therapeutic use.

Dual DNA effects

Animal venom peptides can both damage and protect DNA — genotoxic properties must be assessed before any venom peptide becomes a medicine

What the researchers found

The review identifies two categories of DNA effects from venom-derived compounds:

**Genotoxic effects (DNA damage):**

- Venom peptides like mastoparan, melectin, and melittin (from bee and wasp venoms) can bind DNA and produce DNA breaks

- Crude venoms from jellyfish, scorpions, spiders, and snakes cause DNA damage primarily through cell membrane disruption and subsequent oxidative stress

- Sponge-derived compounds (avarol, variolin B) and sea squirt-derived trabectedin also bind and damage DNA

**Genoprotective effects:**

- Certain animal venoms or their components produce protective effects against DNA damage

- The dual nature (damage vs protection) depends on concentration, target cell type, and specific compound

Both properties have therapeutic relevance — DNA-damaging ability could be harnessed for anti-cancer drugs, while protective effects could aid in preventing mutations.

Why it matters

Venom-derived peptides are a major source of drug candidates — several are already in clinical use. But DNA damage is a serious safety concern that could cause mutations and cancer. This review highlights that genotoxicity testing must be a priority before venom peptides reach clinical use. At the same time, the DNA-damaging properties of certain venom peptides could be intentionally harnessed for cancer treatment, similar to how trabectedin (from sea squirts) is already used as an anti-cancer drug.

How the study worked

This is a narrative review synthesizing published research on the genotoxic and genoprotective effects of biologically active compounds derived from animal venoms. Sources include sponges, sea squirts, bees, wasps, jellyfish, scorpions, spiders, and snakes. The review examines both in vitro DNA-binding studies and cellular genotoxicity assays.

What this study cannot tell us

This is a narrative review with inherent selection bias. Many of the genotoxicity studies cited were performed in vitro under conditions that may not reflect physiological concentrations. The distinction between direct DNA damage and indirect oxidative damage is not always clear in the underlying studies. Most data comes from crude venoms rather than purified peptide components, making it difficult to attribute effects to specific peptides. The clinical relevance of the observed genotoxicity at therapeutic doses is largely unknown.

How to read the evidence

This is a narrative review synthesizing in vitro genotoxicity data from multiple sources. The underlying evidence is primarily from laboratory studies with varying methodologies. While the review raises important safety considerations, the clinical significance of the observed DNA effects at therapeutic doses remains unestablished.

When this study was published

Published in 2023, this review captures the current understanding of venom compound genotoxicity. As venom-derived drug development accelerates, the safety considerations highlighted here remain highly relevant.

The bigger picture

Venom-derived peptides represent one of nature's largest untapped pharmacological libraries. As drug development increasingly turns to these natural compounds, understanding their full biological profile — including effects on DNA that go beyond their primary targets — is essential for safe development. This review fills an important gap by systematically cataloging these 'hidden' effects that could make or break a venom peptide's path to becoming a medicine.

Questions still open

  • At therapeutic concentrations, do venom-derived peptides like melittin cause clinically significant DNA damage?
  • Could the genoprotective properties of certain venom components be developed into drugs that prevent DNA damage from radiation or chemotherapy?
  • How can venom peptides be modified to retain their therapeutic activity while eliminating genotoxic potential?

Common questions

Are venom-based medicines safe if venom peptides can damage DNA?
The key factor is dose and specificity. At the very high concentrations used in laboratory studies, many compounds can damage DNA. At therapeutic doses, the effects may be negligible. Additionally, venom peptides can be modified to enhance desired effects while reducing unwanted ones. Trabectedin, a DNA-damaging compound from sea squirts, is actually used as a cancer drug precisely because its DNA-damaging ability targets cancer cells.
Which venom peptides are already used as medicines?
Several venom-derived compounds are in clinical use. Exenatide (from Gila monster venom) is a GLP-1 receptor agonist for diabetes. Ziconotide (from cone snail venom) treats severe pain. Captopril (inspired by pit viper venom) is a widely used blood pressure medication. Trabectedin (from sea squirts) treats cancer. This review emphasizes that DNA safety should be thoroughly assessed for all such venom-derived therapeutics.

Read the original research

A Review on Genotoxic and Genoprotective Effects of Biologically Active Compounds of Animal Origin.

Toxins, 15(2)

Citation

Sjakste, Nikolajs; Gajski, Goran. (2023). A Review on Genotoxic and Genoprotective Effects of Biologically Active Compounds of Animal Origin.. Toxins, 15(2). https://doi.org/10.3390/toxins15020165